Comparing Costs and Healthcare Resource Utilization (HCRU) Using LAMA versus LABA/ICS at Treatment Initiation for COPD: Findings from CITRUS (Comparing the Incidence of Tiotropium and ICS/LABA in Real-World Use in South Korea) Study

References

• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2023. Available from: www.goldcopd.org. Accessed June 27, 2024.
   Google Scholar
• World Health Organization. Top 10 cause of death 2019 [Internet]. Geneva (CH): World Health Organization; 2020. Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed June 27, 2024.
   Google Scholar
• Naghavi M, Abajobir AA, Abbafati C, et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390(10100):1151–1210.
   PubMed Web of Science ®Google Scholar
• Kim C, Kim Y, Yang DW, et al. Direct and indirect costs of chronic obstructive pulmonary disease in Korea. Tuberc Respir Dis. 2019;82(1):27–34. doi:10.4046/trd.2018.0035
   PubMed Web of Science ®Google Scholar
• Foo J, Landis SH, Maskell J, et al. Continuing to confront COPD international patient survey: economic impact of COPD in 12 countries. PLoS One. 2016;11(4):e0152618. doi:10.1371/journal.pone.0152618
   PubMed Web of Science ®Google Scholar
• Iheanacho I, Zhang S, King D, Rizzo M, Ismaila AS. Economic burden of chronic obstructive pulmonary disease (COPD): a systematic literature review. Int J Chronic Obstr. 2020;15:439–460. doi:10.2147/COPD.S234942
   PubMed Web of Science ®Google Scholar
• Calverley PMA. Guidance for the better care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;201(9):1022–1023. doi:10.1164/rccm.202002-0459ED
   PubMed Web of Science ®Google Scholar
• Bloom CI, Elkin SL, Quint JK. Changes in COPD inhaler prescriptions in the United Kingdom, 2000 to 2016. Int J Chron Obstruct Pulmon Dis. 2019;14:279–287. doi:10.2147/COPD.S190086
   PubMed Web of Science ®Google Scholar
• Choi JY, Milne S, Yunus F, Rhee CK, Matsunaga K. Current chronic obstructive pulmonary disease treatment status in Asia: a position statement of the Asian pacific society of respirology. Tuberc Respir Dis. 2022;85(3):279–282. doi:10.4046/trd.2022.0020
   PubMed Web of Science ®Google Scholar
• Agusti A, Fabbri LM, Singh D, et al. Inhaled corticosteroids in COPD: friend or foe? Eur Respir J. 2018;52(6):1801219. doi:10.1183/13993003.01219-2018
   PubMed Web of Science ®Google Scholar
• Singh D. Blood eosinophil counts in chronic obstructive pulmonary disease: a biomarker of inhaled corticosteroid effects. Tuberc Respir Dis. 2020;83(3):185–194. doi:10.4046/trd.2020.0026
   PubMed Web of Science ®Google Scholar
• Jo YS, Yoo KH, Park YB, et al. Relationship between changes in inhalation treatment level and exacerbation of chronic obstructive pulmonary disease: nationwide the health insurance and assessment service database. Int J Chron Obstruct Pulmon Dis. 2020;15:1367–1375. doi:10.2147/COPD.S248616
   PubMed Web of Science ®Google Scholar
• Zeng Y, Cai S, Chen Y, et al. Current status of the treatment of COPD in China: a multicenter prospective observational study. Int J Chron Obstruct Pulmon Dis. 2020;15:3227–3237. doi:10.2147/COPD.S274024
   PubMed Web of Science ®Google Scholar
• Bogart M, Germain G, Laliberté F, Lejeune D, Duh MS. Real-world treatment patterns and switching following moderate/severe chronic obstructive pulmonary disease exacerbation in patients with commercial or medicare insurance in the United States. Int J Chron Obstruct Pulmon Dis. 2023;18:1575–1586. doi:10.2147/COPD.S398816
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Calverley PMA, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177(1):19–26. doi:10.1164/rccm.200707-973OC
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. Lancet Respir Med. 2018;6(11):855–862. doi:10.1016/S2213-2600(18)30368-0
   PubMed Web of Science ®Google Scholar
• Lee YJ, Rhee CK, Hwang YI, et al. Escalation time to open triple combination therapy from the initiation of LAMA versus ICS/LABA in COPD management: findings from comparing the incidence of tiotropium and ICS/LABA in real-world use in South Korea (CITRUS) study. J Pers Med. 2021;11(12):1325. doi:10.3390/jpm11121325
   PubMed Web of Science ®Google Scholar
• Lee J, Lee JH, Kim JA, Rhee CK. Trend of cost and utilization of COPD medication in Korea. Int J Chron Obstruct Pulmon Dis. 2017;12:27–33. doi:10.2147/COPD.S121687
   PubMed Web of Science ®Google Scholar
• Kim J, Rhee CK, Yoo KH, et al. The health care burden of high grade chronic obstructive pulmonary disease in Korea: analysis of the Korean health insurance review and assessment service data. Int J Chron Obstruct Pulmon Dis. 2013;8:561–568. doi:10.2147/COPD.S48577
   PubMed Web of Science ®Google Scholar
• Kim C, Yoo KH, Rhee CK, et al. Health care use and economic burden of patients with diagnosed chronic obstructive pulmonary disease in Korea. Int J Tuberc Lung Dis. 2014;18(6):737–743. doi:10.5588/ijtld.13.0634
   PubMed Web of Science ®Google Scholar
• Kim J, Kim K, Kim Y, et al. The association between inhaled long-acting bronchodilators and less in-hospital care in newly-diagnosed COPD patients. Respir Med. 2014;108(1):153–161. doi:10.1016/j.rmed.2013.08.003
   PubMed Web of Science ®Google Scholar
• Lim JU, Kim K, Kim SH, et al. Comparative study on medical utilization and costs of chronic obstructive pulmonary disease with good lung function. Int J Chronic Obstr. 2017;12:2711–2721. doi:10.2147/COPD.S143244
   PubMed Web of Science ®Google Scholar
• Yu AP, Yang H, Wu EQ, Setyawan J, Mocarski M, Blum S. Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis. J Med Econ. 2011;14(3):315–323. doi:10.3111/13696998.2011.576295
   PubMedGoogle Scholar
• Pasquale MK, Sun SX, Song F, Hartnett HJ, Stemkowski SA. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population. Int J Chron Obstruct Pulmon Dis. 2012;7:757–764. doi:10.2147/COPD.S36997
   PubMed Web of Science ®Google Scholar
• Park HJ, Byun MK, Kim T, et al. Frequent outpatient visits prevent exacerbation of chronic obstructive pulmonary disease. Sci Rep. 2020;10(1):6049. doi:10.1038/s41598-020-63064-x
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Comparative effectiveness and safety of LABA-LAMA vs LABA-ICS treatment of COPD in real-world clinical practice. Chest. 2019;155(6):1158–1165. doi:10.1016/j.chest.2019.03.005
   PubMed Web of Science ®Google Scholar
• Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of chronic obstructive pulmonary disease. an official American thoracic society clinical practice guideline. Am J Respir Crit Care Med. 2020;201(9):e56–e69. doi:10.1164/rccm.202003-0625ST
   PubMed Web of Science ®Google Scholar
• Mammen MJ, Pai V, Aaron SD, Nici L, Alhazzani W, Alexander PE. Dual LABA/LAMA Therapy versus LABA or LAMA monotherapy for chronic obstructive pulmonary disease. A systematic review and meta-analysis in support of the American thoracic society clinical practice guideline. Ann Am Thorac Soc. 2020;17(9):1133–1143. doi:10.1513/AnnalsATS.201912-915OC
   PubMed Web of Science ®Google Scholar
• Chen CY, Chen WC, Huang CH, et al. LABA/LAMA fixed-dose combinations versus LAMA monotherapy in the prevention of COPD exacerbations: a systematic review and meta-analysis. Ther Adv Respir Dis. 2020;14:1753466620937194. doi:10.1177/1753466620937194
   Web of Science ®Google Scholar
• Wedzicha JA, Buhl R, Singh D, et al. Tiotropium/olodaterol decreases exacerbation rates compared with tiotropium in a range of patients with COPD: pooled Analysis of the TONADO®/DYNAGITO® Trials. Adv Ther. 2020;37(10):4266–4279. doi:10.1007/s12325-020-01438-3
   PubMed Web of Science ®Google Scholar
• Calverley PMA, Anzueto AR, Carter K, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir Med. 2018;6(5):337–344. doi:10.1016/S2213-2600(18)30102-4
   PubMed Web of Science ®Google Scholar
• Rogliani P, Calzetta L, Braido F, et al. LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. Int J Chron Obstruct Pulmon Dis. 2018;13:3115–3130. doi:10.2147/COPD.S170606
   PubMed Web of Science ®Google Scholar
• Barrecheguren M, Monteagudo M, Miravitlles M. Population-based study of LAMA monotherapy effectiveness compared with LABA/LAMA as initial treatment for COPD in primary care. NPJ Prim Care Respir Med. 2018;28(1):36. doi:10.1038/s41533-018-0102-x
   PubMedGoogle Scholar
• Lee SH, Rhee CK, Yoo K, et al. Direct switch from tiotropium to indacaterol/glycopyrronium in chronic obstructive pulmonary disease patients in Korea. Tuberc Respir Dis. 2021;84(2):96–104. doi:10.4046/trd.2020.0109
   PubMed Web of Science ®Google Scholar
• Seon Cheol Park DWK, Eun CP, Cheung SS, Chin KR, Young AK, Young SK. Mortality of patients with chronic obstructive pulmonary disease: a nationwide populationbased cohort study. Korean J Intern Med. 2019;34(6):1272–1278. doi:10.3904/kjim.2017.428
   PubMed Web of Science ®Google Scholar
• Chung SM, Lee SY. Evaluation of appropriate management of chronic obstructive pulmonary disease in Korea: based on health insurance review and assessment service (HIRA) claims. Tuberc Respir Dis. 2017;80(3):241–246. doi:10.4046/trd.2017.80.3.241
   PubMedGoogle Scholar